Elexacaftor/tezacaftor/ivacaftor as rescue therapy in a patient with the cystic fibrosis genotype F508DEL/G1244E.
Donatello SalvatoreCarmela ColangeloMichele D'AndriaGiovanni MarsicovetereDomenica PassarellaPublished in: Clinical case reports (2021)
Elexacaftor/tezacaftor/ivacaftor (ETI) is a cystic fibrosis (CF) transmembrane regulator (CFTR) modulator. It is known to be efficacious in stable patients with severe pneumopathy, but there are few data concerning its effectiveness during acute exacerbations. We here describe its use in a woman with CF and respiratory failure.
Keyphrases
- cystic fibrosis
- respiratory failure
- extracorporeal membrane oxygenation
- pseudomonas aeruginosa
- case report
- mechanical ventilation
- lung function
- randomized controlled trial
- systematic review
- electronic health record
- acute respiratory distress syndrome
- early onset
- big data
- transcription factor
- chronic obstructive pulmonary disease
- stem cells
- drug induced
- liver failure
- mesenchymal stem cells
- artificial intelligence
- air pollution
- data analysis
- aortic dissection